JP Morgan Sec LLC

Allergan plc 38.5(b)

RNS Number : 3540M
J.P. Morgan Securities LLC
08 May 2020
 

Ap27

 

 

FORM   38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.  KEY   INFORMATION

 

Nameofexemptprincipaltrader

J.P Morgan Securities LLC

Companydealtin

Allergan plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 1)

Ordinary Share

Date of dealing

7 May 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   2)

 


Short


Number


(%)

Number


(%)

(1)Relevantsecurities

 4,556,431  1.38

 3,689,394  1.12

(2) Derivatives (other than options)

 3,851,379  1.17

 4,232,350  1.29

(3)Optionsandagreementstopurchase/sell

 305,000  0.09

 0  0.00

Total

 8,712,810  2.64

 7,921,744  2.41

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   2)

 

Classofrelevantsecurity:

Short


Number


(%)

Number


(%)

(1)Relevantsecurities



(2) Derivatives (other than options)



(3)Optionsandagreementstopurchase/sell



Total




Ap28

 

 

3.  DEALINGS  (Note   3)

 

(a)  Purchases and sales

 

Purchase/sale

Numberofrelevantsecurities

Priceperunit (Note 4)

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

9,070

110

100

200

100

25

240

200

200

25

100

33,000

35

14

100

17

224

12

60

1,700

694

700

1,806

2,000

16,000

800

7,600

400

100

100

 

3

4

1

8,888

111

172

3

3

2

1

603

314

1

4

4

2,301

2

1

18,338

33,000

1

10,269

1,001

3

1

5

2

5

3

2

1

1

16,000

66

1

192.9900 USD

193.0500 USD

193.0800 USD

193.0991 USD

193.1064 USD

193.1079 USD

193.1136 USD

193.1375 USD

193.1400 USD

193.2158 USD

193.3600 USD

193.6550 USD

194.1786 USD

194.1900 USD

194.2400 USD

194.2700 USD

194.3598 USD

194.3600 USD

194.3855 USD

194.4259 USD

194.4350 USD

194.4814 USD

194.5294 USD

194.5363 USD

194.5385 USD

194.5463 USD

194.5767 USD

194.5800 USD

194.6900 USD

194.8000 USD

 

192.9200 USD

192.9375 USD

192.9600 USD

192.9900 USD

193.0000 USD

193.0265 USD

193.0700 USD

193.0933 USD

193.1150 USD

193.1200 USD

193.2133 USD

193.2226 USD

193.2300 USD

193.2650 USD

193.4225 USD

193.5086 USD

193.5350 USD

193.5400 USD

193.6525 USD

193.6550 USD

193.7200 USD

193.7295 USD

193.7792 USD

193.9100 USD

193.9500 USD

193.9740 USD

193.9750 USD

194.0100 USD

194.0633 USD

194.1500 USD

194.1600 USD

194.3200 USD

194.5385 USD

194.6607 USD

195.1400 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 5)

Numberofrelevantsecurities

(Note 6)

Priceperunit

(USD)

(Note 4)

Equity Swaps

Long

 

 

Short

194

33,000

 

16,000

192.9900

193.6550

 

194.5385

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing,   selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 4)








 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 4)




 

 

(d)  Other   dealings   (including   transactions   in   respect   of   new   securities)   (Note   3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)





Ap29

 

4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached?  (Note   8)    YES

 

 

Dateofdisclosure

8 May 2020

Contactname

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ap31

 

 

SUPPLEMENTAL   FORM   38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS   OF OPEN POSITIONS

 

(This   form   should   be   attached   to   Form   38.5(b))   OPEN POSITIONS  (Note   1)

 

Productname,

e.g. call option

Written orpurchased

Numberofrelevant securitiestowhichtheoptionorderivativerelates

Exercise price (Note 2)

Type, e.g.American,Europeanetc.

Expiry date

Put Option

Put Option

Written

Written

300,000

5,000

150.00

140.00

American

American

19JUN20

19JUN20

 

 

 

 

Notes

 

1.  Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.  For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEKZGGKGRKGGZM